enVVeno medical, Inc. (Nasdaq: NVNO) is a medical device company focused on the development of innovative bioprosthetic (tissue-based) solutions to improve the standard of care in the treatment of venous disease. The Company’s lead product, the VenoValve®, is a first-in-class bioprosthetic implant being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). Affecting approximately 2.4 million people in the United States, CVI occurs when valves in the veins of the leg become damaged and are not able to move blood back up to the heart, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Implanted into the femoral vein, the VenoValve® is designed to act as a one-way valve, to help restore proper blood flow up the leg. The VenoValve® is currently being evaluated in the SAVVE pivotal study with data expected in late 2022.